ECT
31.1.2020 10:32:09 CET | Business Wire | Press release
ECT (European Computer Telecoms AG), Europe’s leading communications software company for the realization of value-added services, announces that the company again achieved record growth in 2019. The company experienced an annual order intake of over 23 million EUR. Although the company’s audited, consolidated annual report has yet be completed, it is already clear that in 2019 ECT exceeded the 20% top-line growth achieved in the previous year, while the bottom line grew by over 30%. In addition, due to the high order backlog at the close of 2019 and maintenance contracts for 2020, ECT already has more than 12 million EUR on its books for this year and anticipates continued record growth.
This landmark development is in line with the Board’s long-term goal of maintaining at least 20% year-to-year revenue growth. As Marshall E. Kavesh, the CEO and cofounder of ECT, explains, “after more than 20 years as a profitable, but midsized market player, we last year took on the ambitious goal of growing ECT from a 20 million Euro to a 100 million Euro company by no later than 2025. With the excellent results of the last two years we have made important steps in this direction. Our continued growth, profitability, customer relationships and innovations are the foundation for the long-term prosperity and independence of our company. This is a commitment we make to all the colleagues in our fantastic ECT team and especially to our much appreciated customers.”
Key highlights for 2019 include:
Expanded Depth and Breadth of Customer Relationships
- The vast majority of the orders were received from first-tier carriers which have been ECT customers for 10 years and longer, attesting to the deep satisfaction of the company’s customer base.
- In addition, the company, whose roots are in Europe, continued to expand its footprint in the Americas with new customer acquisitions and conducted direct sales worldwide.
- With one of Finland’s leading telecommunications operators, DNA, the company closed a three-year contract worth many millions of euros for the provision of, amongst other things, licenses for ECT’s application for Virtual PBX / Unified Communications, a license for the Service Creation Environment of the company’s Telephony Application Server (TAS) as well as the utilization of a Dedicated Agile Programming Squad .
- In indirect sales via its partner Nokia Software, the company took part in tenders worldwide, e.g. closing yet another major multimillion deal.
Major Investments in Cutting-Edge Telecoms Technology
- The company founded a new R&D unit for NFVi architecture, implemented integration with Nokia’s CloudBand Application Manager (CBAM) and plans to continue certification with other major VNF Managers in 2020. Few competitors are capable of offering this important, cost-reducing technology.
- All new solutions are implemented based on ECT’s VNFs with the option of full integration with a third-party VNF Manager, providing Automated Lifecycle Management.
- ECT implemented agile methodology throughout the company starting in January 2019 and also launched a program allowing CSPs to take under contract an ECT Dedicated Agile Programming Squad, enabling them to respond in extremely short cycles to the customizations and enhancements demanded by their major corporate and municipal customers.
- Within the framework of ECT’s Joint Agile Product Development, the company’s Innovation Department successfully launched its cutting-edge application for unified communications and collaboration, ECT Workspace, with selected CSPs.
Rapid Organization Growth
- Although many other telecoms vendors are in retrenchment, ECT is accelerating the growth of its team: In 2019, the number of employees increased by ca. 25% compared to 2018 and is expected to grow by at least another 25% by the end of this year, the majority of the new positions being in R&D.
About ECT (European Computer Telecoms AG):
For more information about ECT, please visit our website: www.ect-telecoms.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom